Background and Objectives {#Sec1}
=========================

The population in the USA aged ≥65 years has a disproportionately high prevalence of dyslipidemia (65--74 years, 37.1 %; 75--84 years, 37.7 %) \[[@CR1]\] and diabetes mellitus (26.9 %) \[[@CR2]\], both of which are risk factors for cardiovascular disease \[[@CR3]\]. Achieving recommended treatment targets for hypercholesterolemia and diabetes can be difficult with lifestyle modification alone, and typically requires pharmacological therapy \[[@CR4]--[@CR6]\]. It is important to note that although clinical practice guidelines have historically focused on achieving specific low-density lipoprotein cholesterol (LDL-C) targets to reduce cardiovascular disease risk, the recently published American College of Cardiology/American Heart Association guidelines have instead placed the emphasis on reducing risk in patient groups known to be at a high risk for cardiovascular disease, and using the appropriate intensity of statin therapy to reduce risk. The optimal LDL-C goal has remained the same; however, the clinical focus has shifted to who can most benefit from statin therapy as well as using higher-dose statins instead of a low-dose statin combined with a cholesterol-lowering agent from another drug class. These guidelines represent a change in the historical treatment paradigm that is still being debated and is discussed in more detail below \[[@CR7]\].

Standard and intensive doses of statins are effective in reducing LDL-C levels \[[@CR8]\]. However, for patients who are unable to tolerate maximal doses of statins, or who do not achieve treatment targets with such therapy, combination therapy with statins may be necessary. The Lipid Treatment Assessment Project found that National Cholesterol Education Program LDL-C targets were achieved by 40 % of patients receiving statin monotherapy overall and 18 % of those with coronary heart disease (CHD) \[[@CR5]\]. Add-on therapies can enhance the cardiovascular benefits; each mmol/L (39 mg/dL) reduction in LDL-C has been shown to be associated with a 19 % reduction in coronary mortality and a 21 % reduction in risk of any major vascular event (*p* \< 0.001 for both) \[[@CR9]\].

Similarly, an analysis of National Health and Nutrition Examination Survey data (excluding patients likely to have type 1 diabetes) showed that in 2003--2006, hemoglobin A1C (A1C) \<7.0 % was achieved by 57 % of patients overall (64 % of those aged ≥60 years) \[[@CR10]\]. There is a progressive requirement for multiple therapies to achieve glycemic control in patients with type 2 diabetes mellitus (T2DM) \[[@CR11]\]. Nevertheless, each 1 % reduction in A1C has been shown to be associated with a 21 % reduction in risk for deaths related to diabetes and a 14 % reduction in risk for myocardial infarction (*p* \< 0.001 for both) \[[@CR12]\].

Drug safety is an important consideration in the treatment of elderly patients. Indeed, this is among the leading considerations driving the current consensus around the requirement for individualization of treatment for older patients with T2DM who have a longer duration of disease or more complicated disease \[[@CR13]\]. Furthermore, in the USA, the expanding population aged ≥65 years is included in the Medicare population, and it is important in the current climate to show that drugs are safe and efficacious in this population. Although numerous pharmacological options are available for lipid and glycemic control, special care must be taken in prescribing for elderly patients, who may be more susceptible to adverse effects due to age-related changes in pharmacokinetics and pharmacodynamics \[[@CR14], [@CR15]\]. The risk of muscle-related adverse effects associated with 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors (statins), which are considered first-line lipid-lowering therapy, appears to increase with increasing age \[[@CR16]\].

In a study examining hospitalizations for adverse drug events among the elderly population in the USA, two-thirds of hospitalizations were attributable to four drugs or drug classes (alone or in combination); two of these drugs/drug classes were diabetes treatments (insulins 13.9 %; oral antidiabetes drugs 10.7 %) \[[@CR17]\]. Drug-induced hypoglycemia is an important consideration for antidiabetes therapies, particularly sulfonylureas \[[@CR14]\]. Elderly patients with T2DM are at increased risk of hypoglycemia compared with younger patients \[[@CR18]\], leading to increased risk for falls \[[@CR19]\] and fall-related fractures \[[@CR20]\]. In addition, elderly patients with T2DM display unawareness of hypoglycemia relative to middle-aged patients, which may contribute to an increased risk of developing severe hypoglycemia \[[@CR21]\]. Thiazolidinediones are associated with adverse effects that may limit their use in elderly patients \[[@CR15]\]; these include edema and potential congestive heart failure, and fractures \[[@CR14], [@CR22]--[@CR24]\].

Colesevelam hydrochloride is a bile acid sequestrant that was designed to have a high affinity and capacity to bind bile acids. It is unabsorbed by the body and its distribution is confined to the digestive tract. Colesevelam binds to bile acids in the intestine, and these complexes are excreted in the feces \[[@CR25]\], thereby decreasing the bile acid pool. Correspondingly, there is an increased conversion of cholesterol to bile acids that results in a compensatory uptake of LDL-C by the liver from the blood, which ultimately decreases serum LDL-C. The glucose-lowering mechanism of colesevelam is not completely understood; however, it is believed that its binding to bile acids activates a G-protein-coupled receptor for bile acids that results in increased secretion of GLP-1, and perhaps other incretins, which inhibits hepatic glycogenolysis \[[@CR26]--[@CR28]\]. Colesevelam is approved by the US FDA as an adjunct to diet and exercise for the reduction of LDL-C in adults with primary hyperlipidemia (Fredrickson Type IIa) or in boys and postmenarchal girls (aged 10--17 years) with heterozygous familial hypercholesterolemia, as monotherapy or in combination with a statin, and also for improvement of glycemic control in adults with T2DM in combination with oral antidiabetes drugs and insulin \[[@CR29]\]. In double-blind placebo-controlled trials in patients with moderate hypercholesterolemia, colesevelam was shown to be effective in lowering LDL-C levels (13--21 % reduction vs. placebo) and was generally well tolerated \[[@CR25], [@CR30], [@CR31]\], with less constipating effect than other bile acid sequestrants \[[@CR30]\]. In adults with T2DM inadequately controlled by sulfonylurea-, metformin-, or insulin-based therapy, the addition of colesevelam significantly reduced A1C (−0.5 % reduction vs. placebo) and LDL-C levels (13--17 % reduction vs. placebo) and was generally well tolerated in three double-blind, placebo-controlled, parallel-group, multicenter studies \[[@CR32]--[@CR34]\].

Although the safety and efficacy of colesevelam have been well documented in the general population, its safety and efficacy have been less extensively evaluated in older patients. Here, we report the results of post hoc integrated analyses of pooled clinical trial data conducted to evaluate the efficacy and safety/tolerability of colesevelam in older adults (men and women aged ≥65 years) as well as younger adults aged \<65 years.

Methods {#Sec2}
=======

Primary Hyperlipidemia Analysis {#Sec3}
-------------------------------

This was a post hoc analysis of the pooled data from patients with hyperlipidemia (*N* = 1,350) included in seven phase II and III randomized, double-blind, placebo-controlled clinical studies designed to establish the safety and efficacy of colesevelam as a monotherapy or in combination with a statin (lovastatin, simvastatin, or atorvastatin). The studies enrolled patients aged ≥18 years with primary hypercholesterolemia. Patients received colesevelam 1.5--4.5 g/day or placebo for durations ranging from 4 weeks to 6 months. The demographic characteristics of the treatment categories (placebo, colesevelam only, colesevelam/statin, statin only) and colesevelam dose groups (placebo, low, medium, high) created from the integrated database were very similar, with the single exception of duration of exposure. Due to a low number of older patients in the hyperlipidemia studies, no formal statistical analysis had been performed in these studies.

### Efficacy {#Sec4}

A pivotal 6-month phase III dose-ranging study that demonstrated the long-term safety and efficacy of colesevelam monotherapy in a larger patient population was sufficiently large enough for analysis of drug--demographic efficacy interactions. This study included 133 patients aged \<65 years (colesevelam, *n* = 68; placebo, *n* = 65) and 50 patients aged ≥65 years (colesevelam, *n* = 27; placebo, *n* = 23). Efficacy parameters included mean percent changes from baseline to study end in LDL-C and triglyceride levels.

### Safety {#Sec5}

The safety and tolerability analysis included data from all seven studies. These studies included 381 patients aged \<65 years (colesevelam, *n* = 289; placebo, *n* = 92) and 154 patients aged ≥65 years (colesevelam, *n* = 117; placebo, *n* = 37). Safety and tolerability were evaluated on the basis of adverse events (AEs).

Integrated Type 2 Diabetes Mellitus (T2DM) Analysis {#Sec6}
---------------------------------------------------

### Efficacy {#Sec7}

This was a post hoc analysis of the pooled data from all patients (*N* = 1,018) included in three double-blind, placebo-controlled, pivotal trials of colesevelam as add-on therapy for patients with T2DM inadequately controlled with metformin-, insulin-, or sulfonylurea-based therapy \[[@CR32]--[@CR34]\]. The studies enrolled patients aged 18--75 years with T2DM who had A1C values of 7.5--9.5 %. In all three trials, colesevelam (3.75 g/day) or placebo was added on to patients' established antidiabetes therapies for 16 weeks (insulin-based therapy study) or 26 weeks (metformin- and sulfonylurea-based therapy studies). The studies included a total of 790 patients aged \<65 years (colesevelam, *n* = 402; placebo, *n* = 388) and 228 patients aged ≥65 years (colesevelam, *n* = 110; placebo, *n* = 118). Efficacy parameters included mean change in A1C and fasting plasma glucose (FPG), and mean percent changes in LDL-C, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), non-HDL-C, triglyceride, apolipoprotein (apo) A-I, and apo B, from baseline to study end.

### Safety {#Sec8}

The safety analysis included pooled data from the same three pivotal trials \[[@CR32]--[@CR34]\], plus those from a small randomized, double-blind, placebo-controlled pilot study that included patients inadequately controlled on metformin and/or sulfonylureas \[[@CR35]\]. Thus, this safety/tolerability pooled analysis included a total of 249 patients aged ≥65 years (colesevelam, *n* = 121; placebo, *n* = 128) and 880 patients aged \<65 years (colesevelam, *n* = 446; placebo, *n* = 434). One subject aged \<65 years was randomized to colesevelam but did not take the study medication and therefore was not included in the safety analysis. Safety and tolerability were evaluated on the basis of AEs.

Ethical Standards {#Sec9}
-----------------

All clinical studies were conducted in accordance with the ethical principles outlined in the Declaration of Helsinki. The protocol and informed consent documents at each site were approved by an Institutional Review Board. All subjects provided informed consent prior to entering any of the studies.

Results {#Sec10}
=======

Integrated Primary Hyperlipidemia Analysis {#Sec11}
------------------------------------------

### Efficacy {#Sec12}

Colesevelam monotherapy resulted in similar mean reductions from baseline in LDL-C levels compared with placebo in both patients aged ≥65 years (−16.6 % \[*n* = 27\] vs. +0.5 % \[*n* = 23\]) and those aged \<65 years (−13.7 % \[*n* = 68\] vs. +0.4 % \[*n* = 65\]). These changes in LDL-C were accompanied by a similar modest increase from baseline in levels of triglyceride with colesevelam compared with placebo in both patients aged ≥65 years (+13.4 % \[*n* = 27\] vs. +2.9 % \[*n* = 23\]) and those aged \<65 years (+12.7 % \[*n* = 68\] vs. +3.1 % \[*n* = 65\]).

### Safety {#Sec13}

Colesevelam therapy was generally well tolerated in the primary hyperlipidemia studies. The most common AEs were gastrointestinal, including constipation and dyspepsia (Table [1](#Tab1){ref-type="table"}); the incidence of these AEs was similar in both age subgroups.Table 1Adverse events in patients aged \<65 years and ≥65 years in the integrated primary hyperlipidemia analysis occurring in ≥2 % of patients and more frequently in the colesevelam groupAdverse event, *n* (%)\<65 years≥65 yearsColesevelam (*n* = 289)Placebo (*n* = 92)Colesevelam (*n* = 117)Placebo (*n* = 37)Constipation63 (10.3)15 (7.9)26 (13.4)3 (4.4)Dyspepsia54 (8.8)8 (4.2)13 (6.7)1 (1.5)Nausea29 (4.7)8 (4.2)5 (2.6)2 (2.9)Accidental injury21 (3.4)6 (3.2)9 (4.6)1 (1.5)Asthenia25 (4.1)5 (2.6)4 (2.1)0 (0.0)Pharyngitis22 (3.6)4 (2.1)2 (1.0)0 (0.0)Flu syndrome21 (3.4)6 (3.2)4 (2.1)2 (2.9)Rhinitis19 (3.1)7 (3.7)7 (3.6)1 (1.5)Myalgia16 (2.6)1 (0.5)1 (0.5)0 (0.0)

Integrated T2DM Analysis {#Sec14}
------------------------

### Efficacy {#Sec15}

In patients aged ≥65 years as well as those aged \<65 years, colesevelam treatment added to existing therapies resulted in similar reductions from baseline in A1C (Fig. [1](#Fig1){ref-type="fig"}a) and FPG (Fig. [1](#Fig1){ref-type="fig"}b). Adding colesevelam to existing therapies also resulted in similar reductions from baseline in LDL-C and non-HDL-C and similar increases in triglycerides in both age subgroups (Fig. [2](#Fig2){ref-type="fig"}). Both older and younger patients also had similar reductions from baseline in apo B (data not shown) and increases in apo A-I (data not shown) with colesevelam, while no significant changes in HDL-C levels (Fig. [2](#Fig2){ref-type="fig"}) were seen with colesevelam treatment in either age subgroup.Fig. 1Mean changes from baseline in **a** A1C (measured in percentage units) and **b** FPG in the integrated type 2 diabetes mellitus analysis, by age subgroup. *A1C* hemoglobin A1C, *FPG* fasting plasma glucoseFig. 2Mean changes from baseline in LDL-C, non-HDL-C, and HDL-C and median change from baseline in TG in the integrated type 2 diabetes mellitus analysis, by age subgroup. *Asterisk* indicates that the parameter is not normally distributed so median values are reported. The interquartile range values for patients aged \<65 years and ≥65 years were 37.1 and 35.1, respectively. *HDL-C* high-density lipoprotein cholesterol, *LDL-C* low-density lipoprotein cholesterol, *TG* triglyceride

### Safety {#Sec16}

Overall, treatment with colesevelam was safe and generally well tolerated. The overall incidence of AEs was slightly higher with colesevelam than with placebo in both age subgroups, with slightly lower values overall in patients aged \<65 years (Table [2](#Tab2){ref-type="table"}). Serious AE incidence rates in patients aged ≥65 years were lower with colesevelam than with placebo and similar to those in patients aged \<65 years. Maximum treatment-emergent AE severity was mild-to-moderate in the majority of patients in both treatment groups among both age groups. The rate of withdrawals due to AEs was relatively low overall, but slightly higher with colesevelam, compared with placebo, among both patients aged ≥65 years (8.3 vs. 6.3 %) and those aged \<65 years (6.3 vs. 2.3 %), and again slightly lower in the younger subgroup.Table 2Adverse events in patients aged \<65 years and ≥65 years in the integrated type 2 diabetes mellitus analysis occurring in ≥2 % of patientsAE, *n* (%)\<65 years≥65 yearsColesevelam (*n* = 445)Placebo (*n* = 434)Colesevelam (*n* = 121)Placebo (*n* = 128)All TEAEs261 (58.7)236 (54.4)81 (66.9)76 (59.4) Abdominal pain8 (1.8)3 (0.7)3 (2.5)1 (0.8) Arthralgia6 (1.3)8 (1.8)4 (3.3)8 (6.3) Back pain9 (2.0)8 (1.8)2 (1.7)2 (1.6) Bronchitis9 (2.0)10 (2.3)1 (0.8)5 (3.9) Chest pain4 (0.9)4 (0.9)3 (2.5)0 (0.0) Constipation35 (7.9)5 (1.2)14 (11.6)6 (4.7) Cough5 (1.1)11 (2.5)3 (2.5)2 (1.6) Diarrhea9 (2.0)12 (2.8)2 (1.7)4 (3.1) Dizziness5 (1.1)4 (0.9)3 (2.5)1 (0.8) Dyspepsia19 (4.3)6 (1.4)3 (2.5)2 (1.6) Headache8 (1.8)16 (3.7)1 (0.8)3 (2.3) Hypoglycemia10 (2.2)10 (2.3)7 (5.8)3 (2.3) Hypertension10 (2.2)8 (1.8)6 (5.0)1 (0.8) Influenza9 (2.0)13 (3.0)2 (1.7)0 (0.0) Muscle strain1 (0.2)1 (0.2)3 (2.5)1 (0.8) Nasopharyngitis21 (4.7)17 (3.9)2 (1.7)3 (2.3) Nausea14 (3.1)7 (1.6)3 (2.5)1 (0.8) Pain in extremity7 (1.6)4 (0.9)2 (1.7)3 (2.3) Palpitations1 (0.2)0 (0.0)3 (2.5)0 (0.0) Peripheral edema4 (0.9)7 (1.6)3 (2.5)2 (1.6) Pneumonia3 (0.7)1 (0.2)1 (0.8)3 (2.3) Sinusitis10 (2.2)12 (2.8)1 (0.8)1 (0.8) Upper respiratory tract infection24 (5.4)30 (6.9)6 (5.0)5 (3.9) Urinary tract infection14 (3.1)17 (3.9)7 (5.8)5 (3.9) Vomiting10 (2.2)3 (0.7)2 (1.7)0 (0.0)Drug-related TEAEs82 (18.4)37 (8.5)27 (22.3)15 (11.7)Serious AEs22 (4.9)16 (3.7)5 (4.1)10 (7.8)Drug-related serious AEs0 (0.0)0 (0.0)0 (0.0)0 (0.0)*AE* adverse event, *TEAE* treatment-emergent AE

In both age subgroups, the incidence of constipation was higher with colesevelam than with placebo (Table [2](#Tab2){ref-type="table"}). However, the imbalance between treatment groups was less pronounced in patients aged ≥65 years, despite the higher overall incidence of constipation in this subgroup. In both age subgroups, the incidence of diarrhea was lower with colesevelam than with placebo. Dyspepsia was less frequent in patients aged ≥65 years and similar between treatments. Although hypoglycemia was slightly more frequent with colesevelam than with placebo among patients aged ≥65 years, but not those aged \<65 years, no episode of hypoglycemia was considered a serious AE.

It should be noted that the study was not powered to detect statistically significant differences in the incidence of specific AEs between the age cohorts and, therefore, no statistical analysis was performed.

Discussion {#Sec17}
==========

In these integrated analyses, the safety and tolerability profile of colesevelam was generally similar in older patients compared with younger patients. Certain gastrointestinal AEs were slightly more common with colesevelam than with placebo; however, AEs were generally mild-to-moderate and did not often result in drug discontinuation. In addition, colesevelam was effective in lowering LDL-C in patients with primary hyperlipidemia aged ≥65 years; these beneficial effects were similar to those observed in patients aged \<65 years. Furthermore, colesevelam was an efficacious add-on treatment for improving both glycemic control and lipid management in adults with T2DM on various antidiabetes regimens; the effects of colesevelam on diabetic and lipid parameters were consistent in patients aged \<65 and ≥65 years when added to existing antidiabetes therapies. The results from the integrated T2DM study analysis showed that colesevelam had a minimal impact on HDL-C levels, i.e., patients aged \<65 years had an insignificant decrease whereas those ≥65 years had an insignificant increase in HDL-C levels. This is consistent with existing data showing that colesevelam typically has a neutral effect on, or may slightly increase, HDL-C levels \[[@CR29], [@CR36]\].

The selection of pharmacological therapies for older patients requires special care and consideration \[[@CR15]\]. In particular, older patients may be more susceptible to adverse effects \[[@CR14]\], potentially limiting the ability to use certain drugs, or use of higher doses. For example, the incidence of myotoxicity associated with statin therapy appears to increase with increasing age \[[@CR16]\], and is also higher with intensive-dose statin therapy \[[@CR37]\]. The prevalence of diabetes increases with age, and therefore the use of drugs with potential diabetogenic effects in the elderly population is of concern. Niacin has been associated with modest adverse effects on glycemic control \[[@CR38]\], and statin therapy (particularly intensive-dose) has been associated with concerns regarding increased risk of developing diabetes \[[@CR39]--[@CR41]\]. It has been suggested that the cardiovascular benefits of statins outweigh any negative glycemic effects \[[@CR42]\]; however, it may be prudent to avoid any potential increased risk of diabetes in the elderly population. This constitutes yet another consideration for combination or alternative therapies. Colesevelam achieves additive LDL-C reductions of approximately 16 % when used in combination with statins \[[@CR43]\].

Constipation is common in the elderly population \[[@CR44]\]; therefore, the incidence of constipation as an AE may be of particular relevance when treating elderly patients. In the current analyses, while the incidence of constipation was higher with colesevelam than with placebo, as has previously been observed, it was notable that the imbalance between the colesevelam and placebo groups was less pronounced among the older patients, despite the overall incidence of constipation being higher in the older group. Interestingly, in the integrated T2DM analysis, the incidence of diarrhea was lower with colesevelam than with placebo among both age groups. This finding may have been influenced by patients who had study medication added to a regimen that included metformin, which is well known to be associated with the development of diarrhea \[[@CR45]\]. The gastrointestinal effects of metformin, together with weight loss effects, may even be detrimental to frail elderly patients \[[@CR14]\]. Hypothetically, the slightly constipating effects of colesevelam may have somewhat counteracted the diarrhea-inducing effects of metformin, reducing the incidence of diarrhea in the colesevelam group. A similar reduction in diarrhea was seen with colesevelam versus placebo as add-on therapy to metformin in patients with early T2DM in a previous study \[[@CR46]\].

Although tight glycemic control is beneficial in reducing the risk of diabetic complications in patients with T2DM, as shown in the UK Prospective Diabetes Study \[[@CR12]\], avoidance of hypoglycemia is especially important, particularly for elderly patients who may be at increased risk of hypoglycemia \[[@CR18]\], which can lead to falls and fall-related fractures \[[@CR19], [@CR20]\]. Compared with other oral antidiabetes agents, sulfonylureas and repaglinide are associated with a greater risk of hypoglycemia in adults with T2DM \[[@CR47]\]. A consensus panel convened by the American Diabetes Association recommends that glyburide, which has the highest risk of hypoglycemia among the sulfonylureas, should not be prescribed to older patients \[[@CR14]\]. In the current integrated T2DM analysis, the incidence of hypoglycemia was similar with colesevelam and placebo among patients aged \<65 years, and was only slightly higher with colesevelam among patients aged ≥65 years. This increase in hypoglycemia in the older subgroup may have reflected the higher propensity for hypoglycemia in older patients \[[@CR18]\]. Nevertheless, the rates of hypoglycemia remained considerably lower than those reported with other classes of drugs, such as sulfonylureas (up to 36 %) \[[@CR47]\].

Age-specific hypoglycemic data were not analyzed for each of the antidiabetic agent T2DM studies individually; however, the following data are reported in the literature for the colesevelam and placebo total population cohorts to provide a relative assessment of the incidence of hypoglycemia associated with the individual antidiabetic agents in combination with colesevelam. No significant changes in the incidence of hypoglycemia were noted in the small T2DM pilot study wherein colesevelam was added to sulfonylurea and/or metformin \[[@CR35]\]. Colesevelam as add-on therapy to metformin-based therapy \[[@CR32]\] reported one patient in the colesevelam group experienced mild hypoglycemia. Colesevelam as add-on therapy to insulin-based therapy \[[@CR34]\] had a reported incidence of hypoglycemia in the colesevelam versus placebo group of 3.4 and 5.7 %, respectively, and colesevelam as add-on therapy to sulfonylurea-based therapy \[[@CR33]\] reported six patients experienced hypoglycemia versus two patients in the placebo group. No patient discontinued from any of the studies due to hypoglycemia.

One should keep in mind that both renal and hepatic functions diminish with advancing age, requiring consideration in the selection of pharmacological agents in elderly patients \[[@CR48]\]. For example, pharmacokinetic studies of metformin in healthy elderly subjects indicate that plasma clearance is decreased, half-life is prolonged, and peak plasma concentration is increased, due primarily to likely changes in renal function associated with aging \[[@CR49]\]. Another important consideration is the frequent use of polypharmacy among elderly adults and the possibility of drug interactions and altered pharmacokinetics that may result \[[@CR50]\]. Because bile acid sequestrants are not absorbed, they do not cause many of the systemic toxicities that may occur with other classes of lipid-lowering drugs \[[@CR51]\]. In addition, colesevelam has been shown to have a low propensity for drug--drug interactions \[[@CR29], [@CR52]--[@CR55]\]. Where an interaction is apparent with a concomitant medication, the effect can typically be avoided by administration of colesevelam 4 h after the other drug \[[@CR29]\].

Our analyses showed a modest increase in triglyceride levels with colesevelam, the clinical significance of which remains unclear. Elevated triglyceride levels seem to be a synergistic risk factor for CHD rather than an independent risk factor \[[@CR56]\]. In the Lipid Research Clinics Program trial, the risk for CHD was decreased with the reduction of LDL-C even when there was a concurrent modest elevation in triglycerides \[[@CR57], [@CR58]\]. However, a prospective cohort study of an elderly outpatient population showed that a triglyceride level \>200 mg/dL was a significant risk factor for cardiovascular events, irrespective of the presence of hypertension, abdominal obesity, or diabetes \[[@CR59]\]. Confounding the issue even further, the CASTEL (CArdiovascular STudy in the ELderly) study by Mazza et al. \[[@CR60]\] showed that a high triglyceride level was an independent predictor of CHD mortality in elderly women but did not have a predictive role in men. Consequently, additional studies will be needed before a definitive statement can be made regarding the role of triglycerides as a coronary risk factor in older patients \[[@CR60]\]. Presently, we believe the modest triglyceride increase of 15 % in the present study should be interpreted in conjunction with the benefit of colesevelam therapy in reducing LDL-C, non-HDL-C, and apo B levels \[[@CR61]\].

The 2013 American College of Cardiology/American Heart Association guidelines \[[@CR7]\] were published recently; although it was beyond the scope of this study to review these guidelines, it is noteworthy that they focus on reducing atherosclerotic cardiovascular disease risk (ASCVD) and recommend high- and moderate-intensity statin therapy for use in secondary and primary prevention. These guidelines also recommend using the appropriate intensity of statin therapy to reduce ASCVD risk in patients most likely to benefit from such treatment. The guidelines use the intensity of statin therapy as the goal of treatment instead of LDL-C or non-HDL-C targets. As such, non-statin cholesterol-lowering agents can be added if the maximum tolerated intensity of statin treatment results in a less-than-anticipated therapeutic response in patients at higher ASCVD risk. However, it is currently unclear as to how these new guidelines will affect the historical use of non-statin lipid-lowering agents used either as monotherapy or in combination with a statin.

A potential limitation of this study is that the number of older patients evaluated in the hyperlipidemia analyses was relatively small; however, it should be noted that it had a sufficient number of patients to perform statistical analyses. A limitation of the study is that the age range of patients making up the older patient cohort in the integrated T2DM analyses was 65--75 years; consequently, it is not known whether the safety and efficacy findings would also be applicable to patients aged \>75 years. Therefore, caution should be used in extrapolating the data to age groups beyond those evaluated. In addition, the primary hyperlipidemia analysis only included patients who had primary hypercholesterolemia, and the integrated T2DM analysis only included patients with T2DM; thus, the findings from these individual analyses cannot be extrapolated to patients having other types of lipid disorders, metabolic disorders, or both hyperlipidemia and T2DM. Another limitation is that although there are data showing that a bile acid sequestrant can reduce the risk of cardiovascular events \[[@CR58]\], there have not been any randomized clinical trials assessing the effect of colesevelam in improving cardiovascular outcomes/reducing cardiovascular events. Thus, it is currently unknown whether the significant improvement in both the lipid profile and the glycemic control observed with colesevelam administration translates into a reduction in cardiovascular risk in either cohort evaluated. Finally, the data reported in this study were obtained from post hoc analyses of previously conducted pooled analyses rather than performing a meta-analysis of the evaluated colesevelam studies, which would have been more robust statistically. As such, some statistical analyses could not be performed.

Conclusions {#Sec18}
===========

Among both patients with primary hyperlipidemia and patients with T2DM, colesevelam appeared to be generally as safe and well tolerated in patients aged ≥65 years as in those aged \<65 years. In patients aged ≥65 years, colesevelam had similar efficacy to that seen in patients aged \<65 years both for lowering LDL-C levels among patients with primary hypercholesterolemia and for lowering A1C and LDL-C levels among patients with T2DM.
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